Llwytho...
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient populati...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Biomark Res |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5353958/ https://ncbi.nlm.nih.gov/pubmed/28331612 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-017-0093-8 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|